Correspondence| Volume 65, 104021, September 2022

Download started.


Rethinking the algorithm for fatigue management in MS–how the placebo effect can confound clinical expertise


      • Patients with multiple sclerosis (MS) frequently complain of fatigue
      • Neurologists use non-FDA approved prescription drugs early in fatigue treatment
      • These types of drugs may be more dangerous than and only as effective as placebo
      • Physicians may underrecognize the placebo effect in MS fatigue treatment
      • Doctors should use coenzyme Q10 earlier and avoid prescription drugs for MS fatigue


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Adibi I
        • Sanayei M
        • Tabibian F
        • Ramezani N
        • Pourmohammadi A
        • Azimzadeh K.
        Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.
        J Res Med Sci. 2022 Mar 17; 27 (PMID: 35419061PMCID: PMC8995308): 24
        • Nourbakhsh B
        • Revirajan N
        • Morris B
        • Cordano C
        • Creasman J
        • Manguinao M
        • Krysko K
        • Rutatangwa A
        • Auvray C
        • Aljarallah S
        • Jin C
        • Mowry E
        • McCulloch C
        • Waubant E.
        Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
        Lancet Neurol. 2021 Jan; 20 (Epub 2020 Nov 23PMID: 33242419PMCID: PMC7772747): 38-48
        • Bourdette D.
        Are drugs for multiple sclerosis fatigue just placebos?.
        Lancet Neurol. 2021 Jan; 20 (Epub 2020 Nov 23PMID: 33242420): 20-21
        • Malik A
        • Conroy M
        • Turner C.
        Phronesis in Medical Ethics: Courage and Motivation to Keep on the Track of Rightness in Decision-Making.
        Health Care Anal. 2020 Jun; 28 (PMID: 32356112PMCID: PMC7319403): 158-175
        • Finniss DG
        • Kaptchuk TJ
        • Miller F
        • Benedetti F.
        Biological, clinical, and ethical advances of placebo effects.
        Lancet. 2010 Feb 20; 375 (PMID: 20171404PMCID: PMC2832199): 686-695
        • Rief W
        • Nestoriuc Y
        • Weiss S
        • Welzel E
        • Barsky AJ
        • Hofmann SG.
        Meta-analysis of the placebo response in antidepressant trials.
        J. Affect. Disord. 2009 Nov; 118 (Epub 2009 Feb 26PMID: 19246102): 1-8
        • Vijapura S
        • Laferton JA
        • Mintz D
        • Kaptchuk TJ
        • Wolfe D.
        Psychiatrists' Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy.
        Acad. Psychiatry. 2016 Oct; 40 (Epub 2015 Dec 8PMID: 26646406PMCID: PMC4899297): 783-789
        • Rauchová H.
        Coenzyme Q10 effects in neurological diseases.
        Physiol. Res. 2021 Dec 30; 70 (SuppPMID: 35199552): S683-S714
        • Sanoobar M
        • Dehghan P
        • Khalili M
        • Azimi A
        • Seifar F.
        Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial.
        Nutr. Neurosci. 2016; 19 (Epub 2015 Jan 20PMID: 25603363): 138-143